Literature DB >> 36269337

[COVID-19 vaccination strategy for employees of German hospitals: results of a survey of infection control practitioners within the B-FAST project].

Simone Scheithauer1, Anna Bludau2, Stephanie Heinemann3,4, Martina Anton5, Percy Knolle5,6,7.   

Abstract

BACKGROUND AND AIM: At the beginning of the COVID-19 vaccination campaign in Germany, employees in medical facilities were prioritised for vaccination against SARS-CoV‑2 due to the high risk of exposure and contact with vulnerable groups. Hospitals were therefore encouraged to organise and implement the vaccination of their employees as soon as possible. The aim of the study was to record the practice regarding the vaccination strategy for employees in German hospitals.
METHODS: In a self-developed cross-sectional study, infection control practitioners of all German university hospitals as well as non-university hospitals in Lower Saxony and Bavaria were surveyed in March 2021. The data were stratified according to the characteristics of university hospitals and non-university hospitals.
RESULTS: Of 416 invitations sent out, 100 questionnaires (university hospitals: 33; non-university hospitals: 67) were completed. University hospitals reported greater vaccination capacity than non-university hospitals, but a limiting factor was uncertain vaccine supply. Vaccination information campaigns were planned or had already been conducted in 89% of clinics. About two-thirds of the respondents (70%) said they did not plan to conduct antibody tests on vaccinated employees. A follow-up of vaccinated employees to detect possible SARS-CoV‑2 infections by PCR was planned by 41% of the respondents. In case of detection of SARS-CoV‑2 infection, 72% of the respondents had planned further diagnostic procedures. DISCUSSION: All hospitals were able to achieve rapid implementation of COVID-19 vaccination of their employees. At the time of the survey, there was also much uncertainty regarding the management of breakthrough infections as well as the need for booster vaccinations.
© 2022. The Author(s).

Entities:  

Keywords:  Antibodies; COVID-19 testing; Immunization programs; SARS-CoV‑2; Vaccination

Year:  2022        PMID: 36269337     DOI: 10.1007/s00103-022-03607-x

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.595


  10 in total

Review 1. 

Authors:  Ulrike Koock
Journal:  Heilberufe       Date:  2021-02-05

2.  Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.

Authors:  Paul R Wratil; Marcel Stern; Alina Priller; Annika Willmann; Giovanni Almanzar; Emanuel Vogel; Martin Feuerherd; Cho-Chin Cheng; Sarah Yazici; Catharina Christa; Samuel Jeske; Gaia Lupoli; Tim Vogt; Manuel Albanese; Ernesto Mejías-Pérez; Stefan Bauernfried; Natalia Graf; Hrvoje Mijocevic; Martin Vu; Kathrin Tinnefeld; Jochen Wettengel; Dieter Hoffmann; Maximilian Muenchhoff; Christopher Daechert; Helga Mairhofer; Stefan Krebs; Volker Fingerle; Alexander Graf; Philipp Steininger; Helmut Blum; Veit Hornung; Bernhard Liebl; Klaus Überla; Martina Prelog; Percy Knolle; Oliver T Keppler; Ulrike Protzer
Journal:  Nat Med       Date:  2022-01-28       Impact factor: 53.440

3.  Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany.

Authors:  André Nohl; Christian Afflerbach; Christian Lurz; Bastian Brune; Tobias Ohmann; Veronika Weichert; Sascha Zeiger; Marcel Dudda
Journal:  Vaccines (Basel)       Date:  2021-04-23

4.  Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel.

Authors:  Melanie D Swift; Laura E Breeher; Aaron J Tande; Christopher P Tommaso; Caitlin M Hainy; Haitao Chu; M Hassan Murad; Elie F Berbari; Abinash Virk
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

5.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

6.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.

Authors:  Eric J Haas; Frederick J Angulo; John M McLaughlin; Emilia Anis; Shepherd R Singer; Farid Khan; Nati Brooks; Meir Smaja; Gabriel Mircus; Kaijie Pan; Jo Southern; David L Swerdlow; Luis Jodar; Yeheskel Levy; Sharon Alroy-Preis
Journal:  Lancet       Date:  2021-05-05       Impact factor: 79.321

7.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Hein Fennema; Bart Spiessens; Kim Offergeld; Gert Scheper; Kimberly L Taylor; Merlin L Robb; John Treanor; Dan H Barouch; Jeffrey Stoddard; Martin F Ryser; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Nancy Cauwenberghs; Tamzin Tanner; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2021-04-21       Impact factor: 176.079

8.  Evidence for antibody as a protective correlate for COVID-19 vaccines.

Authors:  Kristen A Earle; Donna M Ambrosino; Andrew Fiore-Gartland; David Goldblatt; Peter B Gilbert; George R Siber; Peter Dull; Stanley A Plotkin
Journal:  Vaccine       Date:  2021-05-24       Impact factor: 3.641

9.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.

Authors:  Mark G Thompson; Jefferey L Burgess; Allison L Naleway; Harmony L Tyner; Sarang K Yoon; Jennifer Meece; Lauren E W Olsho; Alberto J Caban-Martinez; Ashley Fowlkes; Karen Lutrick; Jennifer L Kuntz; Kayan Dunnigan; Marilyn J Odean; Kurt T Hegmann; Elisha Stefanski; Laura J Edwards; Natasha Schaefer-Solle; Lauren Grant; Katherine Ellingson; Holly C Groom; Tnelda Zunie; Matthew S Thiese; Lynn Ivacic; Meredith G Wesley; Julie Mayo Lamberte; Xiaoxiao Sun; Michael E Smith; Andrew L Phillips; Kimberly D Groover; Young M Yoo; Joe Gerald; Rachel T Brown; Meghan K Herring; Gregory Joseph; Shawn Beitel; Tyler C Morrill; Josephine Mak; Patrick Rivers; Katherine M Harris; Danielle R Hunt; Melissa L Arvay; Preeta Kutty; Alicia M Fry; Manjusha Gaglani
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-04-02       Impact factor: 17.586

10.  SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST.

Authors:  Stephanie Heinemann; Anna Bludau; Hani Kaba; Percy Knolle; Hajo Grundmann; Simone Scheithauer
Journal:  GMS Hyg Infect Control       Date:  2021-11-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.